Dianthus Therapeutics (DNTH) vs Veradermics (MANE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Dianthus Therapeutics is the larger company by market cap ($4.75 billion vs $4.64 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNTH | MANE |
|---|---|---|
| Share price | $84.88 | $110.95 |
| Market cap | $4.75B | $4.64B |
| 1-day change | -0.61% | +1.83% |
| YTD return | +105.97% | — |
| 1-year return | +144.61% | — |
| 5-year return | -21.17% | — |
| EPS (TTM) | $-4.24 | $-4.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.04M | — |
| Revenue growth (YoY) | -67.35% | — |
| Net income (latest FY) | $-162.34M | $-70.00M |
| Operating margin | -8739.34% | — |
| Net margin | -7973.33% | — |
| 52-week high | $117.88 | $131.24 |
| 52-week low | $32.22 | $32.00 |
| Distance from 52-week high | -27.99% | -15.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +65.88% | +47.36% |
| Average volume | 825.33K | 730.99K |
| Shares outstanding | 55.93M | 41.78M |
| Employees | 92 | 37 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Veradermics
MANE stock →Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
DNTH vs MANE FAQ
Which is bigger, Dianthus Therapeutics or Veradermics?
Dianthus Therapeutics (DNTH) is larger, with a market capitalization of $4.75B compared with $4.64B for Veradermics (MANE).
Are Dianthus Therapeutics and Veradermics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.